Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.
|Articles|May 1, 2004
Special report: For tomorrow's children: Vaccines on the horizon
Valuable as they are, available vaccines have limitations, which keeps the search for new ones going. Here is a preview of what to look forward to in this corner of therapeutics.
Advertisement
Advertisement
Related to this article
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Testosterone changes linked to emotional distress in pubertal girls
2
Tezepelumab sustains EoE remission through 52 weeks
3
Recognizing skin conditions in children with darker skin tones
4
Infant skin care: Choosing products that protect the skin barrier
5